Illumina Inc.

Illumina is engaged in sequencing- and array-based solutions for genetic and genomic analysis. The company provides whole-genome sequencing, genotyping, noninvasive prenatal testing (NIPT), and product support services. Using the company's services, customers can perform whole-genome sequencing projects and microarray projects (including large-scale genotyping studies and whole-genome association studies). The company provides NIPT services through its partner laboratories that direct samples to the company on a test send-out basis in its Clinical Laboratory Improvements Amendments-certified, College of Pathologists-accredited laboratory. The company also provides support services to customers who have purchased its products.
  • TickerILMN
  • ISINUS4523271090
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Due to a more favourable environment, ILLUMINA slightly increases to Neutral

ILLUMINA (US), a company active in the Biotechnology industry, slightly increases its general evaluation. The independent financial analyst theScreener just confirmed the stock market behaviour of the title as moderately risky. At the fundamental level, theScreener confirms the rating of 1 out of 4 stars; given the more favourable environment, the title's overall rating is upgraded to Neutral even if it remains under pressure. As of the analysis date April 13, 2021, the closing price was USD 403.15 and its target price was estimated at USD 325.02.

Illumina, Inc.: New issuer in gene sequencing and cancer screening

Illumina's credit profile is supported by its leading position in gene sequencing and strong cash flow which helps offset higher leverage related to the $8 billion acquisition of GRAIL.

Moody's assigns Baa3 rating to Illumina's notes offering

Rating Action: Moody's assigns Baa3 rating to Illumina's notes offering. Global Credit Research- 16 Mar 2021. New York, March 16, 2021-- Moody's Investors Service, assigned a Baa3 rating to the proposed offering of $1 billion of senior unsecured notes of Illumina, Inc.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of Energy related names are reversing price and RS downtrends. (ex. DRQ, OII, AROC, and CKH) • A few banks and asset managers are inflecting positively or within uptrends. (ex. C, BRKL, VLY, FCF, LM, and INTL) • The healthcare Sector has a number of names inflecting bullishly (ex. CUTR, CMD, IART, CCRN, CRVL, MGLN, PGNX, ANIK, ILMN, IQV, and ANIP)

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Auto Component suppliers are bottoming. (ex. ADNT, DLPH, BWA, DAN, GTX, and LCII) • A number of E&P companies are showing signs of potential bottoms. (ex. PXD, DVN, NBL, EOG, and HES) • Banks and money managers are showing signs of emerging leadership. (JPM, BAC, C, PNC, SBNY, WTFC, IVZ, AMP, SEIC, and MS.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Illumina Inc: 1 director sold

A director at Illumina Inc sold 4,000 shares at 444.610USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Valens Research

Valens Equity Insights and Inflections - 2021 01 12

LPLA has significantly transformed their business returns, but the market is expecting the company to give operational improvements back. The market is expecting UAFRS-based (Uniform) ROA (ROA') to fade from 30% in 2019 to 20% in 2024, with Uniform Asset growth slowing to a modest 5% a year going forward. The market does not think the company's improvement in Uniform ROA from 15%-20% levels historically to towards 30%+ is sustainable, and is expecting the company to see its operating leverage reverse. The market does not appear to recognize that as LPLA has gained scale in both its legacy ...

Valens Research

ILMN - Embedded Expectations Analysis - 2021 01 05

Illumina, Inc. (ILMN:USA) currently trades above corporate averages relative to UAFRS-based (Uniform) earnings, with a 46.5x Uniform P/E. At these levels, the market is pricing in bullish expectations for the firm, but management may be concerned about declining margins, the GRAIL acquisition, and NGS technology Specifically, management may lack confidence in their ability to mitigate margin declines and sustain noninvasive prenatal testing (NIPT) business growth. In addition, they may have concerns about the sustainability of Novaseq and Nextseq demand and the recovery of consumables demand....

Valens Research

Valens Equity Insights and Inflections - 2020 11 17

NFLX currently trades above corporate averages relative to Uniform earnings, with a 44.5x Uniform P/E. At these levels, the market is pricing in expectations for Uniform ROA to improve from 24% in 2019 to 31% in 2024, accompanied by 28% Uniform asset growth going forward. Meanwhile, analysts have even more bullish expectations, projecting Uniform ROA to expand to 37% by 2021, accompanied by 8% Uniform asset growth. However, management appears concerned about growth, cash flows, and churn. Current valuations appear to be pricing in overly bullish expectations for NFLX, and if the company is not...

Valens Research

ILMN - Embedded Expectations Analysis - 2020 11 13

Illumina, Inc. (ILMN:USA) currently trades above corporate averages relative to UAFRS-based (Uniform) earnings, with a 38.1x Uniform P/E. Even at these levels, the market is pricing in expectations for profitability to remain near recent lows, and management may be concerned about academic market uncertainties, TrueSight Software Suite's potential, and sequencing platform development Specifically, management may lack confidence in their ability to secure more sequencing opportunities and sustain innovation momentum across the entire sequencing workflow. Management may also be exaggerating inc...

MarketLine Department

Myriad Genetics Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Myriad Genetics Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Myriad Genetics Inc since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage....

Illumina, Inc.: New issuer in gene sequencing and cancer screening

Illumina's credit profile is supported by its leading position in gene sequencing and strong cash flow which helps offset higher leverage related to the $8 billion acquisition of GRAIL.

Moody's assigns Baa3 rating to Illumina's notes offering

Rating Action: Moody's assigns Baa3 rating to Illumina's notes offering. Global Credit Research- 16 Mar 2021. New York, March 16, 2021-- Moody's Investors Service, assigned a Baa3 rating to the proposed offering of $1 billion of senior unsecured notes of Illumina, Inc.

Moody's assigns a first-time Baa3 issuer rating to Illumina; outlook stable

Rating Action: Moody's assigns a first-time Baa3 issuer rating to Illumina; outlook stable. Global Credit Research- 08 Mar 2021. NOTE: Due to an internal administrative error, the wrong version of this press release was initially published.

Due to a more favourable environment, ILLUMINA slightly increases to Neutral

ILLUMINA (US), a company active in the Biotechnology industry, slightly increases its general evaluation. The independent financial analyst theScreener just confirmed the stock market behaviour of the title as moderately risky. At the fundamental level, theScreener confirms the rating of 1 out of 4 stars; given the more favourable environment, the title's overall rating is upgraded to Neutral even if it remains under pressure. As of the analysis date April 13, 2021, the closing price was USD 403.15 and its target price was estimated at USD 325.02.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch